Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (April 2022)
50 slides from Genprex's investor presentation, Apr 27, 2022
Slide 1: Pioneering Gene Therapies for Large Patient Populations
@). Genprex’ PIONEERING GENE THERAPIES FOR LARGE PATIENT POPULATIONS NASDAQ: GNPX April 2022
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Reform At of 199 iilestones, he effects of Fast. company, any find whatsoever ar granted othe recipient. © Genprex Nasdaq: GNPX
Slide 3: GNPX at a Glance
GNPX AT A GLANCE Genprex,inc. _ GNPX Nasdaq S187 s70m 409K 47,879,708 _$38.6Million. © Genprex Nasdag:GNex 3.
Slide 4: Executive Summary
EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM FIRST SYSTEMIC GENE THERAPY USED FOR CANCER IN HUMANS LARGE MARKETS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING CANCER DRUGS ‘TWO FDA FAST TRACK DESIGNATIONS DEMONSTRATED CLINICAL ACHIEVEMENT TWO LUNG CANCER CLINICAL TRIALS
Slide 5: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE © Genprex Nasdag:GNex 5.
Slide 6: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES © REQORSA is in . py drug candidate addresses Type 1 and, development for cancer. Type 2 diabetes. « Clinical trials include combinations of REQORSA with ‘* May reduce or eliminate daily burden of chec
Slide 7: Oncology Program
ONCOLOGY PROGRAM
Slide 8: Lead Program: Non-Small Cell Lung Cancer
LEAD PROGRAM: NON-SMALL CELL LUNG CANCER RECENT EXPANSION TO SCLC COVERS VIRTUALLY ENTIRE MARKET MOST COMMON LUNG CANCER NscLe TAGRISSO 2021 SALES WORLDWIDE CASES More than two million cases per year worldwide. 236K UNITED STATES, More than 236,000 new cases per year in the U.S. ) Genprex KEYTRUDA 2
Slide 9: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM The first systemic gene therapy delivery platform for cancer GENES SYNERGIES Multiple tumor ‘Advanced approach suppressor genes using combination CANCERS Multiple cancers Genprex Nasdaq: GNP
Slide 10: ONCOPREX Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS (Our pon-vital, biodegradable, th uptoa ae enviconment.. ) Genprex Nasdag:GNex 10
Slide 11: Selective Uptake of REQORSA
SELECTIVE UPTAKE OF REQORSA™ PATIENT 2 PATIENT 1 PRE-TREATMENT BIOPSIES DAP! stain shows lung, cancer cell nuclei POST-TREATMENT BIOPSIES Red stain proximity ligation assay) shows TUSC2 protein expression in patient's cancer calls after veatment, NasoagiGnex 11
Slide 12: REQORSA Targets Cancer at Its Core
REQORSA TARGETS CANCER AT ITS CORE DOTAP: CL-TUSC2 2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS MODULATES IMMUNE RESPONSE Leads to Promot against proliferation cancer Genprex nasonex 12
Slide 13: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS, Genprex Nasdag:GNex 13
Slide 14: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Highest dose used
Slide 15: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS ATIENT EGFR STATUS PRIOR THERAPY Positive (exon 18+20) Complete Response Chemo 3 Negative 24% regression Target Lesion Chemo / anti-PD1 2 30% regression one Target Lesion, Negative: 18% regression all T
Slide 16: EGFR Status/Mutation: REQORSA + Tarceva
EGFR status/mutation REQORSA + TARCEVA COMBINATION swimmer Plot of Best Response, with Time on Study Negative | a Negative 4 SP. Postive (exon 18420) [-*) Negative 4 = Negative 4 2 Ngetie | SD ee Ts) cgatve | A SD Positive (exon 21) | i SD a chevorherspy vee 2 ‘4 Chemotherapy+immunotherapy ca, ee Ss
Slide 17: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN Genprex 7! sczinf nasonex 17
Slide 18: Acclaim-1
Acclaim -1 GENERAL STUDY CHARACTERISTICS + REQORSA in combination with AstraZeneca’ Tagrsso for NSCLC Interim analysis a 25 events (Le, disease progression or FDA Fast Track Designation death) EGR nsctc’ : Tagrsso + Expect to:complete Phase 1 by year-end 2022 + ~ISUS. sites 2-92 patients Phase 1: 9-
Slide 19: Primary Endpoint
PRIMARY ENDPOINT BE «3-3 cose escalation of Dose bring tony rm REQORSA n combination with < & Tagrisso’ PRIMARY ENDPOINT SECONDARY ENDPOINTS + Randomized 1:1, open-label, > Progressio 3 2-arm study of REQORSA in 1 brsimprovement FREQORSA combinalon + Over sina ‘combination with Tagrisso versus Tagri
Slide 20: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Model ~ we 8 . . TUSC2+anti-PD1 combination significantly prolonged TUSC2+anti-PD1 exhibit greater antitumor activity than Painislin allng teases Tade
Slide 21: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda POX tumors developed in humanized mice. Pembro +TU treatment with Keytruda, Genprex NasoagGnex 21
Slide 22: AACR 21: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA MAY OVERCOME RESISTANCE TO KEYTRUDA + CHEMO COMBINATION REQORSA + Keytruda + Chemo + REQOR: metastases in . immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models. on : = teses ee 110" CartorPembro E antor
Slide 23: REQORSA Shows Synergy with Immunotherapy + Chemotherapy
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPY + CHEMOTHERAPY REQORSA + Keytruda + Chemo, A Active T celts (Lung) B reg intung Metastasis © on Lang Matastann em ee | ee REQORSA+anti-PD1+chemo combination resulted in metastasis regression significantly greater than either REQORSA alone or anti-PDI+chemo.
Slide 24: Acclaim-2
at] Acclaim -2 GENERAL STUDY CHARACTERISTICS nscuc : progr FDA Fast Track Designation (received December 2021) ordeath da + Expect to complete Phase 1 by end of Q1 2023, + =10US. sites 2-156 patients Phase 1: Up o 30 patients Phase 2: 126 patients STUDY ARM bose SSCALATIC REQORS KEYTRUDA First progr
Slide 25: Acclaim-2 Endpoints
ali: Acclaim -2 PHASE 1 COMPONENT PRIMARY ENDPOINT 3+3 dose escalation of + Dose limiting toxicity REQORSA in combination with Keytruda PHASE 2 COMPONENT PRIMARY ENDPOINT SECONDARY ENDPOINTS Renae + Progression free survival (PFS) Overall response rate 2-arm study of REQORSA in PES improvement of RE
Slide 26: Scaled-Up Clinical Grade Manufacturing
SCALED-UP CLINICAL GRADE MANUFACTURING MILESTONE POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET Genprex and significantly improved economies of scale. Successful completion of technology wariterand scale-up of REQORS) GMP production process will provide supply for Acclaim clinical
Slide 27: REQORSA in Small Cell Lung Cancer
REQORSA IN SMALL CELL LUNG CANCER ‘Targeting Small Cell Lung Cancer (in addition to NSCLO) allows Genprex to address virtually the entire lung cancer market. ‘Small Cell Lung Cancer: + Consistently has low TUSC2 protein levels Documented to often have deletion of one TUSC2 gene allele Extensive stag
Slide 28: Diabetes Program
DIABETES PROGRAM
Slide 29: Diabetic Patients in Need of Advanced Therapy
DIABETIC PATIENTS IN NEED OF ADVANCED THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS. ‘Type 1 and Type 2 diabetes affect approximately 37 million people in the U.S', or 11 percent of the U.S. population. May replace daily burden of biood glucose ‘monitoring and insulin replaceme
Slide 30: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an ‘AAV vector to deliver the Pdx1 and MafA genes to the pancreas. ‘Transforms alpha cells in the pancreas into ©S,_functional beta-like cells, which can produce insulin to but ar
Slide 31: Key Milestones Through Year-End 2022
KEY MILESTONES THROUGH YEAR-END 2022 Explore new cancer indications Open enrollment for Acclaim-1 Open enrollment for Acclaim-2 Dose the first patient in Acclaim-1 Dose the first patient in Acclaim-2. File protocol for REQORSA + Keytruda for small cell lung cancer Report preclinical data related to
Slide 32: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS Bteraeates Mat Terapeues MRK Nsog romacees SHOX Nosdn Troan TK ston Genpren ine GNP Nasdaq Genprex _ Undxesounsro2;cnvarausPn v2 Melanoma ted an Neck, at NSE Choe “Senponecemia NSCLC, Colorectal Renal Celt Ovarian Solis Tumors, Leukemia NSCLC and sole tumors
Slide 33: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD CATHERINE VACZY, JD Chairman, President & Chief Executive Officer Executive VP, General Counsel & Chief Strategy Officer + 30+ years of expertise in corporate law, including ay: Corporate governance in biotech industry + 20+ years of experience in s
Slide 34: Meet Our Team: Company Management
¥ Genprex MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and 20+ years of expertise in biotech IP law, business jevelopment,ieensing transactions + Seasoned IP executive and attorney DAVID SCHLOSS, JD Senior Vice President, Human Resources + 25+:ye
Slide 35: Meet Our Team: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD, FACS, Chairman s0n Distinguished Clinical + Director, W.M. Keck Center for innovative Cancer TONY S. K. MOK MD, FRCP(C), FHKCP, FHKAM + Professor and Char f clinical Oncol Urea of Hong Rong cofounder ‘of the Lung Cancer Research Gi ay Genprex
Slide 36: Meet Our Team: Clinical Advisory Board
Genprex MEET OUR TEAM CLINICAL ADVISORY BOARD MICHAEL MORSE MD, MHS, FACP- + Professor of Medicine, Division of Medical Oncology inthe Department of Surgery at Duke University Research expertise in targeted therapies and Immunosherapies for cancer, ANDREW BECKER , PHD President and Founder, Becker P
Slide 37: Meet Our Team: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board BRENT LONGNECKER 30+ years of experi in corporate ow ncuing Board Director ‘corporate governance, in biotech ind + Form over of cus Broker colt 6rm + Chief Executive Officer, Longniecker & Associates + 30+ years of experience c
Slide 38: In a Future of Transformational Patient Care
IN A FUTURE OF TRANSFORMATIONAL PATIENT CARE 21ST CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING DRUGS TWO FDA FAST TRACK DESIGNATIONS EXPLORING NEW INDICATIONS AND. PARTNERSHIPS
Slide 39: Genprex Contact
oO Genprex’ NASDAQ: GNPX (877)774- GNPX | investors@genprex.com Nasdaq: GNP
Slide 40: Appendix
Slide 41: Two New Combination Clinical Trials
TWO NEW COMBINATION CLINICAL TRIALS “—=* KEYTRUDA feesiz, — {2 (pembrolizuMab) spcansing = Genprex
Slide 42: Effects of Genetic Alterations in Suppressor Genes
EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES ‘The most common genetic alterations present in NSCLC are located in tumor-suppressor genes against which no targeted agents have been developed. + Regulation of Malignant Tumor Growth + Insensitivty to Growth-inhibitory Signals + Evasions of Progra
Slide 43: Why Systemic Gene Therapy?
WHY SYSTEMIC GENE THERAPY? Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells, No need to atta
Slide 44: Why TUSC2?
WHY TUSC2? 80% of all lung cancer cells lack the TUSC2 tumor suppressor yen Loss or reduction of TUSC2 expression is associated with significantly worse overall survival of ‘TUSC2 compared with normal bronchial epithelia © Genprex Nasdaq: GNPX
Slide 45: Viral vs. Non-Viral Vectors
VIRAL VS. NON-VIRAL VECTORS High level of transfection efficiency Generally stable + Less specictyoftrgtcets Reported cases oF death and causing leukemia Lipoplex Non-Viral Vectors Hip ee aration eieney + Highest: ¢._ Neal parle i cn be muting = Lowest toxicity = Superior: cells . cancer cells, PP g
Slide 46: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN INNOVATIVE MEANS TO SELECTIVELY TARGET CANCER CELLS + The activities of glucose metabolism have a profound impact on the surface of cancer cells A cells lead to a high lactate + Secreted lactate ions remove positive ions, causing cancer cells to
Slide 47: Other Potential Cancer Indications
OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC: pp! gene is associated wit 3p. In addition to NSCLC, other potential indications include: Thyroid Renal Breast Head & Neck Mesothelioma Ovary fonova, AV. Wanov, SV, rude a Mei Cincer 89 (2009 dog tase 459865, ‘eH Muon Wr, Hon JQ, Ren WR Yong
Slide 48: REQORSA + Tagrisso Reduce Tumor Growth
REQORSA + TAGRISSO REDUCE TUMOR GROWTH EFFECT OF TAGRISSO (OSIMERTINIB) + TUSC2 ON A549-LUC METASTASIS ON NSG MICE iB rweys 7 BPARIM Fue 4A TUsce sto. et (simertnib isthe generic form of Tagrisso. Naceag cnx 48
Slide 49: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of Carbo+Pembro+TUSC2 on Tusc2 CarborPembro__+TUSC2 ‘A549 lung met on Hu-NSG % of change (wk2 vs wk5) tumor intensity © Genprex ‘Pembrolizumab is the generic name for Keytruda. Nasdag:GNex 49
Slide 50: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of CarbotPembro+TUSC2 on A549 lung met on Hu-NSG 6*10°9 No treatment J Tusc2 ge M10]= CaborPembro |= Carvo+PembrovTUsC2 & 2x10”. EI = § p14 28 D35 *** p= 0.0003 vs No treatment "p= 0.009 vs Carbo+Pembro "p= 0.02 vs T